Literature DB >> 15635977

A one-year survey of candidemia in Belgium in 2002.

D Swinne1, M Watelle, C Suetens, K Mertens, P A Fonteyne, N Nolard.   

Abstract

A total of 211 episodes of bloodstream yeast infections in 207 patients, hospitalized in 28 Belgian hospitals participating in a National Surveillance Program, were evaluated. A total of 81% of the patients were more than 50 years of age. Candida albicans was the cause of infections in 55% of patients, 22% were due to C. glabrata and 13% to C. parapsilosis. The most common predisposing factors were antibacterial therapy (42%), residence in an intensive care unit (32.9%) and presence of an intravascular catheter (29.7%). Most patients had more than one predisposing factor. Fluconazole alone or in association with another antifungal agent was the treatment of choice for 89.7% of the cases. In vitro susceptibility testing of the isolates revealed that 99% were susceptible to amphotericin B, 95% to 5-fluorocytosine, 82% to fluconazole and 69% to itraconazole. Resistance to azoles was more common among C. glabrata isolates in the elderly. We conclude that the frequency of C. albicans infection is decreasing in Belgium and this is associated with the emergence of other species, most notably, C. glabrata.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15635977      PMCID: PMC2870211          DOI: 10.1017/s095026880400295x

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  12 in total

1.  Use of denaturing high-performance liquid chromatography for rapid detection and identification of seven Candida species.

Authors:  Oliver Goldenberg; Stefanie Herrmann; Thomas Adam; Gina Marjoram; George Hong; Ulf B Göbel; Barbara Graf
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

2.  Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media.

Authors:  Maiken Cavling Arendrup; Guillermo Garcia-Effron; Cornelia Lass-Flörl; Alicia Gomez Lopez; Juan-Luis Rodriguez-Tudela; Manuel Cuenca-Estrella; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

3.  Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers.

Authors:  Arnaldo L Colombo; Marcio Nucci; Benjamin J Park; Simone A Nouér; Beth Arthington-Skaggs; Daniel A da Matta; David Warnock; Juliette Morgan
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

4.  National surveillance of fungemia in Denmark (2004 to 2009).

Authors:  Maiken Cavling Arendrup; Brita Bruun; Jens Jørgen Christensen; Kurt Fuursted; Helle Krogh Johansen; Poul Kjaeldgaard; Jenny Dahl Knudsen; Lise Kristensen; Jens Møller; Lene Nielsen; Flemming Schønning Rosenvinge; Bent Røder; Henrik Carl Schønheyder; Marianne K Thomsen; Kjeld Truberg
Journal:  J Clin Microbiol       Date:  2010-10-27       Impact factor: 5.948

5.  Genotyping of Candida orthopsilosis clinical isolates by amplification fragment length polymorphism reveals genetic diversity among independent isolates and strain maintenance within patients.

Authors:  Arianna Tavanti; Lambert A M Hensgens; Emilia Ghelardi; Mario Campa; Sonia Senesi
Journal:  J Clin Microbiol       Date:  2007-02-28       Impact factor: 5.948

6.  International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Authors:  L Ostrosky-Zeichner; D Kontoyiannis; J Raffalli; K M Mullane; J Vazquez; E J Anaissie; J Lipton; P Jacobs; J H Jansen van Rensburg; J H Rex; W Lau; D Facklam; D N Buell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

7.  Global trends in candidemia: review of reports from 1995-2005.

Authors:  Juliette Morgan
Journal:  Curr Infect Dis Rep       Date:  2005-11       Impact factor: 3.725

8.  Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.

Authors:  Maiken Cavling Arendrup; Guillermo Garcia-Effron; Walter Buzina; Klaus Leth Mortensen; Nanna Reiter; Christian Lundin; Henrik Elvang Jensen; Cornelia Lass-Flörl; David S Perlin; Brita Bruun
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

9.  Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species.

Authors:  K Lagrou; J Verhaegen; W E Peetermans; T De Rijdt; J Maertens; E Van Wijngaerden
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

Review 10.  The effect of biomaterials and antifungals on biofilm formation by Candida species: a review.

Authors:  M Cuéllar-Cruz; A Vega-González; B Mendoza-Novelo; E López-Romero; E Ruiz-Baca; M A Quintanar-Escorza; J C Villagómez-Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-05-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.